Studie kopplar GLP-1-läkemedel till lägre risk för bröstcancer

Svenska

Kvinnor som tar GLP-1-läkemedel som Ozempic och Wegovy uppvisade cirka 30 procent lägre sannolikhet att utveckla bröstcancer i en omfattande observationsstudie.

Forskare granskade elektroniska patientjournaler från mer än 111 000 kvinnor i åldrarna 45 till 80 med ett kroppsmasseindex på 25 eller högre, vilka genomgick bröströntgen vid Penn Medicine mellan januari 2022 och juni 2025. De som ordinerats GLP-1-läkemedel hade 35,1 procent lägre sannolikhet för bröstcancer i hela gruppen och 30,5 procent lägre sannolikhet i en matchad analys. Resultaten presenterades vid 2026 års årsmöte för American Society of Clinical Oncology och publicerades i JCO Oncology Practice. Elizabeth McDonald, professor vid University of Pennsylvania Perelman School of Medicine, påpekade att studien var observationell och inte bevisar ett orsakssamband. McDonald och hennes kollegor planerar att inleda kliniska prövningar för att testa om GLP-1-läkemedel kan bidra till att förebygga bröstcancer hos högriskgrupper. Läkemedlen påverkar signalvägar som är kopplade till cancerutveckling, även om viktminskning också kan bidra till den observerade fördelen.

Relaterade artiklar

Realistic illustration contrasting social stigma: neutral for overweight, positive for exercise weight loss, negative for Ozempic users.
Bild genererad av AI

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Rapporterad av AI Bild genererad av AI Faktagranskad

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

High costs limit access to GLP-1 weight loss drugs

GLP-1 medications such as Ozempic, Wegovy and Zepbound deliver strong health value but create massive budget pressures for insurers. Researchers from the University of Mississippi highlight the gap between cost-effectiveness and affordability. Coverage remains restricted for many eligible patients.

Study links Ozempic to lower depression and anxiety risks

Rapporterad av AI

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Health

Study links PAM gene variants to weaker blood-sugar response to GLP-1 drugs such as Ozempic

Health

Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence

Health

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

Study links GLP-1 drugs to modest hair loss risk

A new analysis of patient records shows that adults with type 2 diabetes who take GLP-1 receptor agonists face a higher rate of alopecia than those on other common diabetes medications.

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Rapporterad av AI Faktagranskad

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

Semaglutide linked to slower epigenetic aging signals in small HIV trials, researchers report

Semaglutide, the active ingredient in Ozempic and Wegovy, was associated with slower changes in DNA methylation–based “epigenetic clocks” in adults living with HIV in a post hoc analysis of a randomized, placebo-controlled trial. Scientists say larger studies are needed to determine whether these molecular signals translate into meaningful long-term health benefits.

Fibre boosting GLP-1 hormone approved for EU foods

Rapporterad av AI

A modified fibre known as inulin-propionate ester has received safety approval from the European Food Safety Authority, paving the way for its addition to everyday products such as breads and cereals.

26 juli 2026 00:20

Oral GLP-1 drugs reduce food reward signals in mice

24 juli 2026 01:53

Stanford scientists report appetite-suppressing peptide that reduced weight in mice and pigs

16 juni 2026 07:37

Claims-data study finds many people with type 2 diabetes restart GLP-1 drugs after stopping

15 juni 2026 07:24

Oral GLP-1 pill shows strong results in diabetes trial

14 juni 2026 20:36

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

24 maj 2026 12:15

AI analysis of Reddit posts highlights potential underrecognized side effects linked to GLP-1 drugs

22 maj 2026 11:06

Study finds GLP-1 hormone at very low levels in arthritic joint fluid

21 maj 2026 22:41

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

12 maj 2026 00:48

Semaglutide shows strong weight loss results for adults over 65

8 maj 2026 00:46

Trojan horse obesity drug boosts weight loss in mice

Denna webbplats använder cookies

Vi använder cookies för analys för att förbättra vår webbplats. Läs vår integritetspolicy för mer information.
Avböj